SR-878 / SciRhom - LARVOL DELTA

Study Investigating the Safety, Tolerability and Blood Concentration of the Substance SR-878 (clinicaltrials.gov) - P1 | N=18 | Terminated | Sponsor: SciRhom GmbH | N=48 ➔ 18 | Trial completion date: Aug 2025 ➔ Feb 2025 | Recruiting ➔ Terminated | Trial primary completion date: Aug 2025 ➔ Feb 2025; Sponsor decision

Enrollment change • Trial completion date • Trial primary completion date • Trial termination

Study Investigating the Safety, Tolerability and Blood Concentration of the Substance SR-878 (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: SciRhom GmbH | Not yet recruiting ➔ Recruiting

Enrollment open

Study Investigating the Safety, Tolerability and Blood Concentration of the Substance SR-878 (clinicaltrials.gov) - P1 | N=48 | Not yet recruiting | Sponsor: SciRhom GmbH

New P1 trial

SciRhom Secures EUR 63 Million Series A Financing Round to Accelerate iRhom2-targeting Therapies in Autoimmune Diseases (GlobeNewswire) - "SciRhom GmbH...announced today the closing of a EUR 63 million (USD 70 million) Series A financing round...The new funds will be used to accelerate and broaden the impact of the company’s innovative therapeutic strategy in autoimmune disorders. The first clinical study evaluating SR-878, a highly specific monoclonal antibody for iRhom2, is expected to start dosing in the second half of 2024...Based on positive preclinical data sets generated in vitro and in established animal models of rheumatoid arthritis (RA) and inflammatory bowel disease (IBD), SciRhom has advanced its first program to a Phase 1-ready stage. As announced on June 12th, 2024, the first CTA approval was achieved paving the way for initiating a first clinical study in Austria in the second half of 2024."

Financing • New P1 trial • Immunology • Inflammatory Bowel Disease • Rheumatoid Arthritis